PubMed Health⌕ Search

PubMed · 7523746

[Interferon and diseases].

Abstract

Interferon (IFN) is part of the body's natural defense system. IFN production is a cellular response to the foreign constituents of microbes, tumors and antigens. The three types (alpha, beta and gamma) of IFN proteins differ both structurally and antigenically and have molecular weights ranging from 16,000-25,000 daltons. The IFN proteins induce antiviral, antimicrobial, antitumor, and immunomodulatory actions. We reviewed the recent studies on the relation between IFN and diseases concerning; 1) the IFN-alpha and -gamma producing capacity in patients with cancers, liver cirrhosis, diabetes mellitus and rheumatoid arthritis, 2) endogenous IFN in sera and exudates or extracts of local lesions obtained from patients with immunological diseases such as SLE, sarcoidosis, rheumatoid arthritis, Behçet's disease, and psoriasis, 3) deletion of IFN-alpha and -beta genes in human lymphoblastoid cells lines and leukemia, and 4) the expression of IFN and other cytokine (interleukins and TNF) mRNA in normal organs under physiological conditions. Although IFNs may play an important role in cancers and immunological diseases, it is necessary to consider the interactions between IFNs and other cytokines as IFN is one of the factors involved in the cytokine network in vivo.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Kita. 1994. [Interferon and diseases].. https://pubmed.ncbi.nlm.nih.gov/7523746/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues.

The purification of animal insulin preparations and the use of human recombinant insulin have markedly reduced the incidence but not completely suppressed the occurrence of insulin allergy manifestations. Advances in technologies concerning the mode of delivery of insulin, i.e. continuous subcutaneous insulin infusion (CSII), and the use of insulin analogues, resulting from the alteration in the amino acid sequence of the native insulin molecule, may influence the immunogenicity and antigenicity of native insulin. Instead of increasing allergy reactions, CSII has been reported to represent a successful alternative treatment in diabetic patients presenting local or generalized allergy to insulin or other components (zinc, protamine) of conventional treatment. Most recent reports concern CSII-treated patients using short-acting insulin analogues (essentially insulin lispro), although the precise role of these insulin analogues remains unclear as allergy to them has also been described. Finally, data on antigenicity and immunogenicity of long-acting insulin analogues (glargine, detemir), which may mimic the basal insulin delivery with CSII, remain scarce at present.

Diabetes Mellitus↗

Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease.

Insulin deficiency is known to be associated with a state of increased muscle protein breakdown; this process is mediated by the ubiquitin-proteasome pathway. Convincing in vitro data are further supported by extensive studies in humans with insulin deprivation and are further substantiated by reversal of muscle protein breakdown with insulin treatment. In patients with end-stage renal disease (ESRD) and diabetes mellitus (DM), muscle protein breakdown is enhanced in both acute and chronic conditions. Recent data also point to the potential protein catabolic effects of insulin resistance combined with insulin deficiency. Because ESRD is associated with a state of insulin resistance, uremic muscle wasting may also be mediated by this pathway.

Diabetes Mellitus↗